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ABSTRACT
Introduction: Ten years after its introduction into clinical microbiology, MALDI-TOF mass spectrometry
has become the standard routine identification tool for bacteria in most laboratories. The technology
has accelerated analyses and improved the quality of results. The greatest significance has been
observed for bacteria that were challenging to be identified by traditional methods.
Areas covered: We searched in existing literature (Pubmed) for reports how MALDI-TOF MS has
contributed to identification of rare and unknown bacteria from different groups. We describe how
this has improved the diagnostics in different groups of bacteria. Reference patterns for strains which
yet cannot be assigned to a known species even enable the search for related bacteria in studies as well
as in routine diagnostics. MALDI-TOF MS can help to discover and investigate new species and their
clinical relevance. It is a powerful tool in the elucidation of the bacterial composition of complex
microbiota in culturomics studies.
Expert opinion: MALDI-TOF MS has improved the diagnosis of bacterial infections. It also enables
knowledge generation for prospective diagnostics. The term ‘hard-to-identify’ might only be rarely
attributed to bacteria in the future. Novel applications are being developed, e.g. subspecies differentia-
tion, typing, and antibiotic resistance testing which may further contribute to improved microbial
diagnostics.
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1. Introduction
Before MALDI-TOF mass spectrometry (MS) had become
a routine technology in laboratories of clinical microbiology,
classical phenotypical tests, in particular, based on biochem-
ical properties like the fermentation of sugars, were the com-
mon standard methods to identify and describe yet unknown,
potentially pathogenic microorganisms. Generally, these tests
start from pure colony material and need at least an overnight
incubation. Thereby, the identification of even fast-growing
bacteria is delayed by one day, and this delay becomes even
longer for slow-growers.
Further, the differentiation of closely related bacteria just
based on biochemical characteristics is difficult or impossible
in a considerable number of cases. This is especially a problem
for microorganisms with few characteristic biochemical reac-
tions like non-fermenting gram-negative bacteria or anae-
robes. This might lead to misidentifications with negative
consequences for treatment.
Even more problematic are very rare or yet undescribed
bacteria for which reliable references for biochemical profiles
may be missing completely. MALDI-TOF MS has changed this
situation dramatically [1]. Many previously hard-to-identify
bacteria now can be easily characterized by their protein
profile spectra. The time needed for definitive identification
has reduced to minutes starting with a single small colony,
regardless of the kind of microbe, thereby the result is avail-
able within one day for most bacteria. And even many bacteria
with very similar phenotypical characteristics can now be
easily differentiated.
This review will give an overview of the progress which has
been made in recent years. Dedicated custom databases for
research studies and the improvement of the commercially
available databases have recently enhanced the capability to
detect bacteria from groups that have been difficult to iden-
tify. Large studies and clinical routine usage of MALDI-TOF MS
systems have uncovered bacteria which were not previously
recognized as clinically relevant, some of them even not
defined as an individual species.
2. MALDI-TOF MS for identification of bacteria
Generally, cultured microorganisms are necessary for MALDI-TOF
MS identification because a sufficient number of cells is necessary
for spectra acquisition, i.e. about 5 × 105 cells on a target spot [2].
The standard routine workflow inmost laboratories starts with the
transfer of a small amount of biomass from a colony grown on an
agar plate to a sample position of a MALDI target plate. The
bacterial biomass is overlaid with one µl of a solution containing
a special matrix which is necessary for the MALDI process. After
drying, the target plate is introduced into the mass spectrometer
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formeasurement. For somemicroorganisms, well-adapted sample
preparation protocols have been established to improve the effi-
cacy of protein extraction from the biomass. In the vacuum of the
MALDI-TOF instrument, the matrix including the embedded pro-
teins is evaporated by a pulsed laser beam. The biomolecules are
ionized and accelerated by high voltage, then separated accord-
ing to their mass/charge ratio (m/z) in a flight tube. The resulting
mass spectrum depicts the m/z on the x-axis and the intensity
(number of molecules at a certain mass) on the y-axis. The spectra
are compared to pre-established databases according to the algo-
rithms of the respective manufacturers. A comparison of MALDI-
TOF MS with other frequently used methods for identification of
bacteria is given in Table 1.
Today, systems provided predominantly by two different
manufacturers are in use in the vast majority of laboratories
performing MALDI-TOF MS–based microorganism identifica-
tion, i.e. the MALDI Biotyper (Bruker Daltonik GmbH,
Germany) and the Vitek MS (bioMérieux, France). Both are
available as research-use-only (RUO) and in-vitro diagnostic
(IVD) versions. These two different systems both acquire pro-
tein/peptide mass spectra in the range of 2000–20,000 m/z;
however, the bioinformatic approaches differ fundamentally.
The MALDI Biotyper uses a pattern matching approach [3]
with a database containing individual references, each called
MSP. A newly acquired spectrum is converted to a peak list
which is then compared to all MSPs of the MALDI-TOF refer-
ence database. The similarity of the spectrum to each refer-
ence is calculated and expressed as a ‘log(score)’ with values
between 0 and 3. The reference with the highest log(score)
value, i.e. the highest similarity, is the basis of the identifica-
tion. A log(score) ≥2 indicates a ‘high confidence identifica-
tion’, log(score) ≥1.7 and <2 gives a ‘low confidence
identification’ for gram-positive and gram-negative bacteria.
Log(scores) <1.7 are interpreted as ‘no reliable identification’.
For mycobacteria, the thresholds are adopted to log(score)
≥1.8 (high confidence) and ≥1.6 (low confidence), respectively
[4]. For research purposes, these acceptance criteria have
often been modified according to the personal experience of
the authors. The bioinformatic approach is the same for both
the RUO and IVD version of the MALDI Biotyper. In contrast,
the Vitek MS is using two different bioinformatic systems in
the IVD and RUO mode. The Vitek MS IVD uses an algorithm
based on supervised machine learning, the ‘Advanced Spectra
Classifier’, for identification [5]. The spectra between 3,000 and
17,000 Daltons are divided into 1300 segments (‘bins’) which
are weighted according to their importance for identification/
differentiation of a species. An unknown spectrum is also
‘binned’ and compared to the Vitek MS ‘Knowledge Base’.
Results are given as percentages, with a perfect match having
a value of 99.9%, >60% to 99.8% are considered as good.
Scores <60% are considered as no valid identification. The
SARAMIS system (RUO of Vitek MS) is working with
a database of so-called ‘Super Spectra’, reference peak lists
with weighted marker peaks. SuperSpectra are computed
from typical strains covering intraspecific diversity in species.
Identification of unknown strains is performed by comparison
to all SuperSpectra in the database followed by a ranking
according to similarity. Confidence levels are given as high
(>98%) to medium (85% to 98%) to low (75% to 85%) [6].
Detailed information can be found in the product informa-
tion presentations on the websites of each manufacturer of
the MALDI Biotyper [7] and Vitek MS [8]. The ASTA MicroIDSys
[9] is not currently in use in Europe or the United States, and
limited information is available on this system.
3. MALDI-TOF MS: performance for challenging
organism groups
3.1. Aerobic bacteria
Aerobic bacteria from several taxonomic entities have been diffi-
cult to identify or differentiate by traditional methods. Soon after
the introduction of MALDI-TOF MS into clinical routine,
a significant improvement in these areas could be observed. The
continuous enhancement of reference databases could further
advance the performance of MALDI-TOF MS.
3.1.1. Nonfermenters
Among the first groups that have been thoroughly investigated
were gram-negative non-fermenting aerobic bacteria,
a heterogenous group of microbes which are difficult to iden-
tify by classical methods because of their lack of characteristic
biochemical reactions. Nonfermenters can be ubiquitous in the
environment and are responsible for a broad spectrum of
(opportunistic) infections. Although the performance of
MALDI-TOF MS was superior to biochemical systems [10]
some closely related groups could not be differentiated and
results ended at the group or even genus level. These limita-
tions are also known for 16S rRNA gene sequencing. In addition,
the permanent evolution of microbial taxonomy created new
species which represented a new challenge for identification.
In 2011, 3 years after the first comprehensive studies for
nonfermenting bacteria using MALDI-TOF MS, a new species
Elizabethkingia anophelis was described. The type strain was
isolated from the midgut of a mosquito and is closely related
to E. meningoseptica and E. miricola [11]. Just shortly after its
description, it was found that the new species could cause
healthcare-associated outbreaks with high morbidity and high
mortality [12]. Although commercial diagnostic systems at that
Article highlights
● MALDI-TOF MS has significantly improved the identification of many
previously hard-to-identify bacterial groups. This is particularly true
for gram-negative nonfermenting bacteria, bacteria from the HACEK
group, anaerobes, and mycobacteria.
● New species which are introduced by new phylogenetic insights or
new discovery can easily be integrated into MALDI-TOF MS
databases.
● Renaming of species is a further challenge in clinical microbiology.
● Permanent database update and curation is required.
● Culturomics studies benefit from MALDI-TOF MS and are feeding the
databases.
● Novel algorithms can further improve differentiation of closely
related species or subspecies.
● Detection of subtypes, e.g. for resistance or virulence detection, is
extending the scope of MALDI-TOF-MS in the microbiology
laboratory.
● MALDI-TOF MS-based phenotypic susceptibility testing might be
a promising option for the future.
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time were not able to securely differentiate Elisabethkingia
species, the new species Elisabethkingia anophelis could be
identified by MALDI-TOF MS during an outbreak in Wisconsin
using an in-house database at the Centers for Disease Control
in Atlanta [13]. This demonstrates the possibility of rapid
adaption of a MALDI-TOF system for an emerging pathogen
by expert users (see below). Supplementing the SARAMIS
database of the Vitek MS research-use-only (RUO) system
also enabled the correct identification of E. anophelis [14].
Figure 1 depicts the overall similarity of mass spectra acquired
from strains of the three main species of Elisabethkingia and
characteristic peak patterns which can be used for their differ-
entiation. Nielsen and coworkers reported the limitations of
current MALDI-TOF MS systems in the identification of
Elisabethkingia species [15]. An update of the MALDI Biotyper
database and a supporting subtyping functionality are in pre-
paration for 2019 (own unpublished results). But meanwhile,
three further species of the genus have been proposed which
might require further updating of existing databases [16].
The genus Acinetobacter is an example of howmicrobial identi-
fication is being challenged by taxonomic evolution. It has under-
gone significant taxonomical changes during the recent years.
Several new species have been described, which poses
a challenge for all identification systems. The flexibility and high
discriminative power of MALDI-TOFMS enable the rapid adoption
of databases to offer an up-to-date identification result for diag-
nostics. Again, as nonfermenters, these species are common in the
environment and also can be found as part of the normal flora of
the human skin. The members of the Acinetobacter baumannii
complex are especially clinically important as they may cause
severe nosocomial infections. Furthermore, they tend to be epi-
demic in hospitals and are therefore important for questions of
hospital hygiene and infection control.
Espinal and coworkers reported the capability of MALDI-
TOF MS to differentiate species from the A. baumannii group,
i.e. A. baumannii, A. pittii, and A. nosocomialis [17]. The authors
concluded that the improvement in differentiation within this
group might offer the chance to learn about their
epidemiology and allow for targeted therapeutic and infection
control measures. Marí-Almirall and colleagues included
further novel species, A. seifertii and A. dijkshoorniae, into the
MALDI Biotyper database to extend the scope of identification
inside the A. baumannii group [18]. To improve the differentia-
tion of these closely related species they used the ClinProTools
software (Bruker Daltonik, Germany) which enabled the utili-
zation of species-specific peaks when the standard approach
did not work. A later study investigated the performance of
the MALDI Biotyper for the 18 Acinetobacter species described
at that time [19]. As six of the novel species were not included
in the commercially available database, additional reference
spectra for those were added by a custom database. While this
extension of the database only partially improved identifica-
tion, use of an alternative MALDI matrix (ferulic acid) allowed
the correct identification of nearly all problematic strains. Such
an approach required a two-step or parallel preparative
approach which could be too laborious for rapid routine
diagnostics. It has to be investigated if a further search for
differentiating mass peaks may lead to an alternative algo-
rithm to overcome current limitations.
A previously underestimated pathogen, Wohlfahrtiimonas
chitiniclastica, gained attention after introduction of MALDI-
TOF MS into routine microbiology laboratories. Before 2014,
the bacterium which lives in larvae of an obligate parasitic
fly was only detected two times in human blood samples.
As biochemical tests could not identify the microorganism,
16S rRNA gene sequencing had to be applied. With the
spread of MALDI-TOF MS and the extension of its database
with reference patterns of more rare microbes, the number
of reports from several continents for this zoonotic patho-
gen as a cause of human diseases significantly increased
[20]. Flies are potent vectors for the distribution of
W. chitiniclastica causing local or systemic infections origi-
nating from wounds infected with fly larvae but also other
transmission routes have been described. Infections in
humans include wound infections, cellulitis, osteomyelitis,
and sepsis [20].
Figure 1. Extremely similar MALDI-TOF mass spectra from three different Elisabethkingia species, E. miricola, E. meningoseptica, and E. anophelis. No differentiating
features are obvious.
a) Pseudo-gel view of mass spectra from the three Elisabethkingia species, E. miricola, E. meningoseptica, and E. anophelis, zoom in the region of m/z 7000–8000. Two strains of each species
are depicted, at least 20 spectra per strain. Arrows point to potentially species-specific peaks.
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Also, Myroides odoratus and Myroides odoratimimus are rare
non-fermenting human pathogens. These bacteria have been
regarded as non-pathogenic for humans for decades. But an
increasing number of case reports now indicate that both
species are human pathogens. Besides urinary tract infections,
soft tissue infections (including cellulitis and necrotizing fas-
ciitis) and sepsis have also been associated with Myroides spp.
Mostly (but not only) immunocompromised patients are
affected. To date, new species (Myroides injenensis, Myroides
pelagicus, Myroides profundi, Myroides marinus, Myroides
phaeus, Myroides xuanwunensis, Myroides indicus, and
Myroides gitamensis) have been added to the genus
Myroides. However, clinical cases are only related
to M. odoratus and M. odoratimimus. Therefore, these two
species need to be specially considered by both microbiolo-
gists working in diagnostic laboratories and clinicians. In this
regard, it is essential to reliably identify to species level. For
this reason, the suitability of MALDI-TOF MS (MALDI Biotyper,
Bruker Daltonik, Germany), sequencing of the 16S rRNA gene
and biochemical characterization by VITEK2 (bioMérieux,
France) for identification of M. odoratus and M. odoratimimus
have been compared. MALDI-TOF MS and sequencing could
securely distinguish both species [21]. Applying VITEK2, it was
only possible to obtain the genus Myroides, but not the dis-
tinct species.
Both M. odoratus and M. odoratimimus are highly resistant
against multiple antibiotics, especially ß-lactams and aminogly-
cosides [22]. Therefore, definitive identification allowed the study
of the individual susceptibility profiles of Myroides odoratus and
Myroides odoratimimus separately for the first time [22].
3.1.2. HACEK group
Identification of bacteria from the so-called HACEK group, i.e.
belonging to the genera Haemophilus, Aggregatibacter,
Cardiobacterium, Eikenella, and Kingella, has benefitted from
the introduction of the MALDI-TOF MS technology [23,24].
These bacteria are involved in infective endocarditis and
cause the majority of cases of gram-negative endocarditis
[25]. In a recent nationwide population-based study of
HACEK bacteremia in Denmark, the authors highlighted the
benefit of the use of MALDI-TOF MS compared to traditional
methods for identification [26]. MALDI-TOF MS was shown to
be suitable for discrimination of H. influenzae from closely
related H. haemolyticus which are considered to be much
less pathogenic [27,28], and it even has the potential for
capsular typing of H. influenzae [29].
3.1.3. Corynebacteria
Identification of species from the genus Corynebacterium and
other coryneform-like bacteria has been considerably
improved by the introduction of MALDI-TOF mass spectro-
metry [30]. Although these bacteria are frequently considered
as contaminants as they are often part of the normal flora of
the human skin, a study investigating 246 gram-positive rods
isolated from blood cultures of 181 patients and identified by
MALDI-TOF MS revealed that about one third had to be con-
sidered as pathogenic, highlighting the clinical significance of
this improvement in diagnostics [31].
3.1.4. Nocardia
Another challenging group of bacteria for routine identifica-
tion are Nocardia species. These gram-positive and partially
acid-fast bacteria can be ubiquitous in the environment and
are not part of the human flora. Some species may cause
infections, primarily in immunocompromised patients. The
clinical manifestations range from superficial infections occur-
ring also in immunocompetent people, e.g. by inoculation into
skin lesions, to pulmonary or systemic disease. Identification
was initially performed using a large set of biochemical tests,
but as many species are nonreactive reliable results were
difficult to obtain and molecular methods have been proven
to be more precise and rapid [32]. Now MALDI-TOF MS has
also become a suitable alternative for routine use.
For identification of Nocardia species, different protocols exist
for the different MALDI-TOF systems on the market. While the
MALDI Biotyper uses the same method as recommended for
other bacteria, the Vitek MS identification is based on an extrac-
tion using bead-beating of the cells. Both methods and systems
have been shown to achieve high-quality results in multicenter
studies [33,34]. A report of McTaggart and coworkers described
that bead-beating has little impact on identification success by
MALDI-TOF MS while analysis of early growth is crucial. The
authors recommended culture media that promote quick
growth of Nocardia [35]. But it might be that these findings are
dependent on the MALDI-TOF MS system used and how the
database references have been created.
3.1.5. Bite wound infections
Further aerobic bacteria which are rare and hard-to-identify by
traditional methods have been reported to benefit from MALDI-
TOF MS-based identification, and the number is still growing. As
an example, among these are bacteria causing infections after
a dog bite. Species from different genera can now be detected
with a higher accuracy by MALDI-TOF MS compared to traditional
biochemical tests, e.g. species from the genus Pasteurella [36],
Capnocytophaga [37], or Mycoplasma [38].
3.2. Anaerobic bacteria
Anaerobes have always been challenging in medical micro-
biology. First, because until the mid-1960s proper anaerobic
culture conditions for isolation of colonies on the surface of
culture media were lacking in routine laboratories. Later, the
isolated anaerobic bacteria (often causing mixed infections)
were only reported as ‘mixed anaerobes present’ to the clin-
icians, as classical identification methods were too time-con-
suming due to the inactivity of the bacteria in automated or
miniaturized biochemical tests. Another major drawback of
conventional identification methods used is the amount of
biomass needed, which is a particular problem with slow-
growing anaerobes, producing tiny colonies even after 48
h of incubation in proper anaerobic conditions. Therefore,
with regard to the different clinically relevant organism groups
in medical microbiology, identification of anaerobic bacteria
has probably benefited most from the introduction of the
protein profile-based approach by mass spectrometry.
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Already the early studies with MALDI-TOF MS-based identi-
fication of frequently isolated gram-negative anaerobic bac-
teria, such as Bacteroides, Prevotella, Porphyromonas or
Fusobacterium species proved the superiority of the new tech-
nology with results on species or genus level in a very timely
manner even from limited amounts of biomass [39–42].
Furthermore, MALDI-TOF MS allowed separation of species
like, e.g. P. nigrescens and P. intermedia, which previously
could only be differentiated by sequencing and not with
biochemical tests or gas-liquid chromatography [39,41].
The good performance in identification was also shown for
the gram-positive anaerobic rods like clinical and environmen-
tal Clostridium spp., again with the possibility to differentiate
closely related species like C. chauvei and C. septicum [43], or
for usually biochemically inactive gram-positive anaerobic
cocci (GPAC) and Actinomyces spp. [44,45].
The convenience in the workflow and the robustness of
identification of anaerobic bacteria by MALDI-TOF MS could
also be proven by investigations of the pre-analytical condi-
tions. Neither different culture media, which are essential for
anaerobes, nor the short exposure to oxygen impaired the
correct identification [43,46–48]. High-quality spectra for anae-
robes can be acquired after 24–48 h of incubation, and direct
spotting of biomass from suitable colonies followed by an on-
target extraction with 70% formic acid is usually sufficient. Full
extraction may only be important in routine for some groups
such as GPAC and Actinomyces spp [48,49]. As intensive spor-
ulation may cause deviations in fingerprint patterns, extended
incubation time may deteriorate species identification of clos-
tridia [43,50].
Although the first studies showed good results, the quality
of the identification was limited by the coverage of the avail-
able databases, as some frequently encountered species such
as C. hathewayi, Parabacteroides distasonis, Bacteroides
eggerthii, B. goldsteinii, B. intestinalis, and Prevotella heparino-
lytica were missing in the database and therefore could not be
identified [3,40,42]. A review evaluating the performance of
MALDI-TOF MS systems for identification of anaerobes com-
paring results published between 2010 and 2012 showed that
correct species-level identification varied between 55% and
93.8% depending on the number of tested isolates and the
number of different anaerobic species and genera investi-
gated in the different studies [51]. This underlined the need
for further development of databases for a broader applicabil-
ity in a clinical routine which was also shown by a European
ring trial with participants using different databases and yield-
ing different performances based on the coverage of the
databases [49]. In addition, an increasing number of publica-
tions about less frequently isolated or even newly described
anaerobic species (e.g. Solobacter moorei, Robinsoniella sp.,
Sneathia sanguinegens, Eisenbergiella tayi, Collinsella aerofa-
ciens, Atopobium rimae, and many others) causing severe
infections and often leading to sepsis [52–56] aroused the
interest of more laboratories for identification of anaerobic
clinical isolates to species level. For this, MALDI-TOF MS
seemed to be a suitable method in routine laboratories.
The first database development studies were mainly con-
ducted by reference laboratories for anaerobes. The manufac-
turer’s databases were extended with missing anaerobic
species taken from culture collections or with well-character-
ized isolates from clinical routine whose species-level identifi-
cation had been confirmed by 16S rRNA gene sequencing
[40,42,44,45].
A more general approach for database extensions with
regard to anaerobes was undergone by the ENRIA project
(European Network for the Rapid Identification of Anaerobes)
which was supported by the Study Group for Anaerobic
Infections (ESGAI) by the European Society of Clinical
Microbiology and Infectious Diseases (ESCMID). The main
objective was the collection of clinically relevant anaerobic
isolates in collaborating laboratories from different European
countries for addition to the database of the Bruker MALDI
Biotyper system.
In particular, species missing completely or which were
represented with less than five strains in the reference data-
base were targeted by the ENRIA collection [57,58]. To ensure
a high-quality standard for the MALDI-TOF MS references, the
collected strains were identified by classical methods as well
as 16S rRNA gene sequencing. The newly created references
were added to the database and finally also released for
common use in routine laboratories.
The validation of the ENRIA database development was
performed with 6309 independent anaerobic strains isolated
from human clinical specimens over a period of 6 months. The
validation collection comprised species from 61 different com-
mon and rare anaerobic genera [57,58]. Compared to the
standard database the initial ENRIA database extension
allowed an increase in identifications at the high confidence
species level from 71.1% to 74.8%. In parallel, the number of
isolates with low confidence identification decreased (16.9%
to 14.9%) as well as the isolates without identification (12.0%
to 10.4%). Adding all ENRIA MSPs to the database even further
improved the identifications at high confidence level to 4999
of the 6309 anaerobic isolates (79.2%), and low confidence
identification was achieved for 852 isolates (13.5%). Overall,
35.2% of the isolates yielded higher score values with the
database extension. This could be accomplished not only for
less frequent isolates (such as Solobacter moorei, Bacteroides
massiliensis, Bacteroides clarus, Bacteroides cellulosilyticus,
Prevotella salivae, or Prevotella timonensis), but also for more
commonly occurring species of Bacteroides, Prevotella,
Fusobacterium, or GPAC [58].
Moreover, the ENRIA database extension also enabled iden-
tification of several recently described and rare species from
different genera, e.g. Dielma fastidiosa, Moryella indoligenes,
Fenollaria massiliensis, Filifactor alocis, and Odoribacter splanch-
nicus, providing routine laboratories the capability to assess
their potential clinical importance [57,58]. Nonetheless, there
were still 458 (7.3%) strains which could not be identified even
with the ENRIA database extension.
The coverage of the MALDI-TOF MS databases may be
important to laboratories for their effectiveness in clinical
routine. A recent paper [59] showed that at the beginning of
2018 both the FDA-cleared and the RUO database of the
MALDI Biotyper comprised a considerably higher number of
genus level (FDA 19/RUO 59) and species level (FDA 63/RUO
359) entries of anaerobes compared to the VITEK MS (FDA 11
and 26/RUO 24 and 103, respectively). Another study
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compared the two main MALDI-TOF MS systems used in rou-
tine for the identification of less common, but clinically rele-
vant anaerobes and microaerophilic bacteria. The 221 strains
studied, most of them isolated from blood cultures (n = 131),
covered 112 species of 49 genera. After direct spotting, 29.9%
and 34.3% of gram-positive (n = 137) as well as 36.9% and
58.3% of gram-negative isolates (n = 84) were identified at the
species-level with the VITEK MS and the Biotyper, respectively.
Performing full extraction significantly increased the rates of
correct species-level identification with the Biotyper system for
both gram-positive (78.1%) and gram-negative (78.6%) iso-
lates. Nevertheless, it is evident that the accuracy of both
systems needs to be further improved by expanding the
databases [60].
The impact of MALDI-TOF MS for clinical routine can, for
example, be seen in the Anaerobic Bacteriology Laboratory at
the Mayo Clinic (USA). Since the introduction of the new
technology in 2011, not only the turn-around-time of final
identification of anaerobes was considerably reduced, but
also the hands-on-time of technologists. Firstly, classical phe-
notypic tests could be replaced by rapid MALDI-TOF MS iden-
tification, and secondly, technologists spent on average only
4.49 min with MS-based identification compared to 23.85 min
with sequencing-based methods [59]. Since anaerobes that
were previously hard to identify by classical methods could
now easily be classified by mass spectrometry, the need for
16S rRNA gene sequencing dropped considerably.
Despite the advantages of MALDI-TOF MS for anaerobes,
there are still limitations in identification by the protein pro-
files. Examples for this are the discrimination of Bacteroides
dorei from Bacteroides vulgatus, and between Bacteroides ova-
tus and Bacteroides xylanisolvens. Here, besides 16S rRNA gene
sequencing, some specific biochemical tests, such as the β-
glucosidase and catalase test, respectively, allow differentia-
tion of clinical isolates belonging to these species [53]. These
limitations also became evident during the ENRIA validation
study. Similar problems were also found for Porphyromonas
asaccharolyticus and Porphyromonas uenonis [57].
On the other hand, several studies have shown that detailed
analysis of mass spectra can be used for differentiation of closely
related species or even subtyping within species. As an example,
Clostridium sporogenes and Clostridium botulinum, usually impor-
tant but difficult to differentiate, can be correctly identified to
species level by mass spectrum analysis in combination with
methods of multivariate statistical analysis (developing the
C. sporogenes/C. botulinum ‘training database’) [61]. The same
method was even able to differentiate the isolates belonging to
various metabolic groups of C. botulinum [61].
Such differentiation (subtyping) may also have clinical rele-
vance in routine laboratories. So, using the SARAMIS software
package (4.0.0.14 bioMérieux), MALDI-TOF MS can rapidly and
automatically identify F. nucleatum to the subspecies level,
including subsp. animalis, nucleatum, polymorphum, and fusi-
forme/vincentii. This may improve knowledge about their
pathogenicity, epidemiology, and clinical impact [62].
Another example for subtyping with high clinical impact is
the differentiation of the two divisions of B. fragilis which was
described independently by two groups applying different
strategies [63,64]. Various PCR-based methods have proven
that only B. fragilis isolates belonging to division II harbor
a gene named cfiA, responsible for the production of a strong
carbapenemase that causes a broad resistance towards impor-
tant antibiotic agents. Wybo et al. [63] applied the composite
correlation index tool of the MALDI Biotyper, and dendrogram
calculation clearly separated B. fragilis isolates belonging to
division I from those of division II. In the other study, the spectra
of well-characterized cfiA-positive and -negative B. fragilis
strains were evaluated by the ClinProTools software (Bruker
Daltonik) [64]. MS peaks (4826, 9375, 9649 m/z) were found to
be characteristic for division II B. fragilis isolates. Several further
studies using this subtyping proved the applicability in routine
to give early warnings to clinicians about the presence of the
cfiA gene in clinical isolates prior to time-consuming classical
susceptibility testing [65–70]. The subtyping functionality for
B. fragilis divisions I and II is now implemented in the MALDI
Biotyper RUO software and will become part of the IVD-CE
labeled system during 2019.
Likewise, differentiating the main phylogroups IA, IB, IC, II,
and III of Cutibacterium (Propionibacterium) acnes was possible
[71]. Phylogroup-specific peaks and peak shifts were identified
visually and included in a differentiating software prototype.
Altogether, 48 C. (P.) acnes clinical isolates were successfully
typed with results identical to MLST typing.
MS-based typing may also be important for outbreak inves-
tigations in hospitals. As an example, two approaches were
tested for the typing of Clostridioides (Clostridium) difficile to
find a more rapid and less expensive typing method than the
usually applied PCR ribotyping [72,73]. Firstly, unique protein
peaks within MALDI-TOF mass spectra of C. difficile were used
by Reil et al. [72]. Secondly, the high molecular weight (HMW)
protein profiling from whole cells in the mass range of 30–50
kDa [73] showed the possibility of grouping C. difficile strains
according to their surface layer proteins. This approach was
less discriminatory than PCR ribotyping, but it is a good option
to monitor hospital outbreaks. During a recent study, several
hospital outbreaks with C. difficile were diagnosed by the rapid
application of the HMW typing and it was shown that even
further subtyping can be performed [74].
3.3. Mycobacteria
To date, more than 180 mycobacterial species have been
described. The most well-known are the members of the
Mycobacterium tuberculosis complex as the causative agent
of tuberculosis, and M. leprae. Besides these, the remaining
species are usually summarized as ‘non-tuberculous mycobac-
teria’ (NTM). Mycobacterial species of this heterogenous group
are ubiquitous in the environment and, for instance, can be
found in soil and water. They are usually regarded as bacteria
with a moderate pathogenicity which can cause opportunistic
infections [75].
Although rare in general, the awareness for infections with
NTM has risen in recent years: On the one hand, the number
of described NTM species has grown from about 50 in 1997 to
more than 125 in 2007 [76], and since then more than further
50 new species have been described. Only a small portion of
these are familiar to clinicians [75]. On the other hand, an
increasing incidence and prevalence of diseases caused by
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NTM at various body sites has been observed [75] as well as
a growing number of infections in immunocompetent
individuals.
With the growing number of possibly clinically relevant species,
DNA probe-based assays also reached their limitations in coverage
and discriminatory power due to cross-reactions and not fully
specific probes [75]. As a reference method for identification of
mycobacteria sequencing of housekeeping genes (e.g. for 16S
rRNA, hsp65, rpoB) is used [75]. With regard to the high technical
requirements, this is mainly performed in specialized reference
laboratories. The introduction of MALDI-TOF MS as a method for
identification of mycobacteria offered new possibilities, and eva-
luations show good results [4,77]. The instruments are available in
many laboratories now and databases today have a broad cover-
age of NTM species.
Unlike other bacteria, mycobacteria need special extraction
methods as the amount of ribosomal proteins is low and the
cell walls are more rigid so, for example, silica beads are used
for mechanical disruption during the extraction of mycobac-
terial proteins [78].
The protein extraction is possible from biomass harvested
from solid media as well as from cells grown in liquid media
like MGIT which are broadly used for culture of mycobacteria.
Especially the direct extraction from the liquid media of auto-
mated incubation systems allows timely identification of NTM
species. Alcaide et al. have published overviews of sample
processing [79].
The current databases for MALDI-TOF MS identification of
mycobacteria comprise almost all currently known species of
mycobacteria. The discriminatory power of MALDI-TOF MS for
identification of mycobacteria seems to be sufficient for most
of the species. There are limitations in differentiation between
very closely related species, e.g. members of the
Mycobacterium tuberculosis complex cannot be separated
from each other. In other cases, subtyping by peak analysis
of the mass spectra may allow differentiation of species with
little genetic differences [80]. All in all, the broad coverage of
the MALDI-TOF MS databases enables laboratories to identify
even rare NTM species that could not have been identified or
would have been misidentified with former routine methods.
A more accurate species identification also offers the oppor-
tunity to learn more about the pathogenicity and prevalence
of these mycobacteria.
A comprehensible example for the possible impact of pre-
cise identification even of assumed rare bacteria is
Mycobacterium chimaera: Sax et al. published about an inves-
tigation in 2012 of a prolonged outbreak of infections
with M. chimaera after open-chest heart surgery [81]. They
identified six cases with prosthetic valve endocarditis or vas-
cular graft infection due to M. chimaera, 1.5 to 3.6 years after
surgery. As a source of the infection, the heater-cooler units
used in open-heart surgery were suspected, as indicated by
cultures from the water circuits of the devices as well as from
air samples collected during usage of the units. It turned out
that it was a global outbreak related to the contaminated
heater-cooler units with more than 100 cases worldwide [82]
M. chimaera is a member of the Mycobacterium avium
complex (MAC), and separation from M. intracellulare is espe-
cially challenging. Even molecular identification of M. chimaera
is difficult, and different genes were proposed for differentia-
tion by DNA-based method: 16S rRNA gene sequencing was
suggested for accurate differentiation by Sax et al. [81] while
Schweickert and coworkers found the ITS sequence more
suitable for this purpose [83]. Ben Salah et al. used 16S rRNA,
ITS, rpoB and hsp65 to distinguish within the MAC [84]. The
widely used DNA probe-based assays identified M. chimaera
as M. intracellulare and although MALDI-TOF MS showed very
good discriminatory power with its broad database, there
were limitations with M. intracellulare/M. chimaera as well.
This was finally overcome by analysis of the MALDI-TOF mass
spectra for distinct peaks specific for M. chimaera
and M. intracellulare [80]. Now, this has also been automated
in subtyping modules for the MALDI-TOF MS systems that can
automatically differentiate between the two species.
Usage of these new possibilities in clinical routine shows
that M. chimaera is the prevalent species in comparison
to M. intracellulare. With DNA probe-based assays these isolates
were usually (mis)identified as M. intracellulare (Pranada, unpub-
lished data). The more accurate identification will provide future
knowledge of the clinical relevance of these two species.
Therefore, identification methods used in clinical routine like
MALDI-TOF MS and also molecular methods have to be re-eval-
uated continuously for their discriminatory power, especially
when the microorganisms are rare in general, and when new
species are described. Due to the awareness for M. chimaera, for
example, the current molecular assays have also been adapted to
differentiate accurately betweenM. chimaera andM. intracellulare.
A recent study by Epperson et al. evaluating the differentiation
of M. intracellulare/M. chimaera by MALDI-TOF MS by comparing
to sequencing results from different gene loci and even data from
whole-genome sequencing shows that the phylogeny might be
more complex as certain strains identified by MALDI-TOF MS
as M. intracellulare cluster more closely with M. chimaera in WGS
although they are relatively distant from any available reference
[85]. This again underlines the need to include new knowledge
about taxonomy and phylogenetic relations of references and
clinical strains into the identification methods available for routine
diagnostics.
3.4. Highly pathogenic bacteria
A general problem for routine laboratories is the unforesee-
able but occasional appearance of highly pathogenic bacteria.
This is not a new problem arising with MALDI-TOF MS but
there is a residual risk of infection during the sample prepara-
tion process for MALDI-TOF MS, in particular, if good labora-
tory practice is not applied. This risk should be considerably
lower compared with the risk arising from aerosols during
sample preparation for automated biochemical identification
when appropriate McFarland suspension densities are
adjusted. On the other hand, the rapid identification of
a highly pathogenic microorganism by mass spectrometry
enables the rapid recognition and then proper handling of
the respective organisms in the remaining workflow, reducing
the time of possible exposure to laboratory staff [86].
Nevertheless, laboratories should be aware that not all highly
pathogenic bacteria can be differentiated from less patho-
genic closely related species [87] and that databases
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comprising references for highly pathogenic bacteria have to
be implemented and included explicitly in routine. In a recent
study about misidentification of highly pathogenic microor-
ganisms by MALDI-TOF MS in Canada in the time from
November 2015 to October 2017, at least six of eight reported
misidentifications occurred on systems which were not
equipped with a respective database or where the available
database was not used [88].
4. Culturomics
The increasing awareness of the importance of the human
microbiome for health and diseases has induced a growing
number of studies. The investigation of microbiome composi-
tion, its dynamics, and activity today are mainly based on
genomic technologies like 16S rDNA sequencing or metage-
nomic shotgun sequencing in combination with powerful
bioinformatic approaches and computational tools [89].
These approaches enable the detection and quantification
even of non-cultivatable microorganisms; however, they are
hampered by biases introduced by experimental protocols
and data-cleaning approaches [90]. In 2012, a strategy for
the investigation of complex microbiota called ‘culturomics’
was described as an alternative and complementary approach
to metagenomics [91]. The principle proceeding in culturomics
is the cultivation of microorganisms on a broad variety of solid
media to obtain as many different microbial colonies as pos-
sible. Subsequently, the obtained colonies are used as starting
material for identification of the respective microorganisms. As
tens of thousands of single colonies have to be investigated in
such a study, here MALDI-TOF MS as a very rapid, accurate
technology with low costs per identification plays a key role.
The comprehensive databases which are available today
already enable the identification of a large number of these
colonies. But the utility of MALDI-TOF MS is not limited to the
identification of known microorganisms in this approach.
Colonies which cannot be identified using existing databases
undergo 16S rRNA gene sequencing for identification. In par-
allel, new database entries are created for these strains.
Identification by DNA sequencing enables the species desig-
nation of the new references in the extended database.
Sometimes DNA sequence analysis does not result in the
identification of a known species, but a yet unnamed taxon is
detected [92,93]. The MALDI-TOF MS reference created from
this unknown species can nevertheless be used for further
simple screening of this new undescribed microorganism. An
iterative approach of screening of more colonies and addition
of new reference entries allows the detection of rare as well as
of novel species which to date have no name. The drawback
of this method is the enormous effort in sample preparation,
in particular, the cultivation of microorganisms under many
different conditions and the manual picking of many thou-
sands of colonies. DNA-based methods have the advantage to
detect microorganisms which cannot currently be cultivated
and thereby are missed by culture-dependent techniques.
Culturomics studies have proven to detect a significant num-
ber of bacterial species which are missed by culture-free tech-
niques [94,95].
While the very complex gut microbiome has been investi-
gated initially and most intensely, the analysis of other micro-
biota also offers new insights into bacterial composition which
might impact future diagnostics or therapy. The investigation
of the microbial flora of the vagina revealed several species
which had not been described before [96].
In a study that aimed to evaluate the bacterial richness and
diversity of the skin in ICU patients, it was found that daily
bathing with chlorhexidine was associated with substantial
shifts of skin microbiota and a reduction in richness and
diversity of bacteria, in particular gram-negatives [97]. Also in
this study, several novel bacteria were detected.
Further microbiota investigated by culturomics were
obtained, e.g. from diabetic foot [98], human oral cavity and
respiratory tract [99], and the mosquito gut [100]. In all these
studies, novel species or species which had not been asso-
ciated with the respective habitats before were found.
It is obvious that these huge culturomics studies extend
our knowledge about microbiological diversity, in particular of
the human microbiota which could be extended by 400 spe-
cies, 288 of those newly described [101]. Yet, it is not clear to
what extent the approach will improve the understanding of
human diseases, diagnostics, and treatment of infections. It
has been speculated that through the knowledge gained by
such studies, keeping and reconstructing an optimized gut
microbiome might prevent the occurrence of human diseases
[102]. As an example, irreversible disruption of gut microbiota
is suspected in most severe cases of malnutrition, leading to
persistent impaired development or death. The alimentation
with selected probiotic microorganisms detected by culturo-
mics studies might improve the treatment of such cases
through the re-establishment of a healthy gut micro-
biota [103].
On the other hand, the direct involvement of newly
detected species has to be verified in most cases. In contrast
to metagenomic studies, the culturomics approach has
a significant advantage here as the novel species are available
as cultures and can be thoroughly investigated. Reference
profiles can be incorporated into MALDI-TOF MS databases
for further studies. After export of the references and their
transfer to other laboratories, they can be utilized also at other
institutions for investigation of a broad variety of routine
samples from clinical microbiology. As the mass spectra of
MALDI-TOF identification in routine are stored electronically,
even retrospective analyses for the occurrence of novel spe-
cies in microbial diagnostics are possible. Thereby, new data
and insights from MALDI-TOF MS-based culturomics studies
can directly feed into microbial diagnostics using MALDI-TOF
mass spectrometry.
5. Library expansion for rare bacteria
The manufacturers of the currently available MALDI-TOF MS
systems have continuously extended the databases and
libraries with new reference spectra for clinical use (as exam-
ple, the development of the Bruker MALDI Biotyper databases
for bacteria is depicted in Table 2). With growing species
diversity in the databases, the total number of different genera
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and species effectively reported in a routine laboratory also
increases significantly [78].
The extensions of databases usually also include rare bac-
teria. An example for this is Actinotignum schaalii (formerly:
Actinobaculum schaalii) where MALDI-TOF MS with the corre-
sponding reference spectra was the first routine suitable
method that enabled correct identification. Now evidence
shows that this species can be found quite often in clinical
samples and is recognized as a relevant pathogen [104]. This
underlines the value of extensions of the databases as it may
also add to the future knowledge in medical microbiology.
For RUO, laboratories can even create custom reference
spectra (main spectra, MSP) and expand the existing data-
bases with new microorganisms or for special applications.
In Pubmed, a tremendous amount of publications about
MALDI-TOF MS employing custom databases are listed.
Other publications, especially about newly described spe-
cies, provide reference spectra or MSP libraries for inclusion
into custom databases. There are also platforms for the
exchange of reference spectra between users (e.g. MALDI-
UP) [105]. A fundamental prerequisite of such database
expansions is the secure species identification by
a reference method or even a combination of suitable
methods and a rigorous quality control during reference
establishment.
Current software versions of the Bruker Biotyper system allow
export and import of custom MSPs for easy direct exchange of
MSPs between users.
With these possibilities, laboratories can also detect new or
rare bacteria that are not yet included in the officially released
database libraries. Figure 2(a) shows an example from
a routine laboratory (MVZ Dr. Eberhard & Partner Dortmund,
Dortmund, Germany) of a mass spectrum acquired from
a bacterium cultured from an ear swab in April 2012.
Table 2. Development of the MALDI Biotyper databases during the recent years,
number of included species (a) General IVD-CE labeled database/bacteria &
yeast.
Database version Release year No. species Gram + Gram -
(a) General IVD-CE labeled database/bacteria & yeast
DB 4613* 2012 2144 1111 923
DB 5627* 2013 2257 1138 946
DB 5989* 2015 2329 1164 973
DB 6763 2016 2380 1172 1015
DB 7171 2017 2428 1205 1030
IVD 7712 2018 2665 1274 1189
IVD 8326 2019 2887 1411 1266
(b) Mycobacteria database
Mycobacteria db v1.0 2012 94
Mycobacteria db v2.0 2014 131
Mycobacteria db v3.0 2015 149
Mycobacteria db v4.0 2016 159
Mycobacteria db v5.0 2017 164
Mycobacteria db v6.0** 2019 178
*These versions were including several MSPs of mycobacteria and molds which
were removed in 2016.
**First IVD-CE labeled mycobacteria database.
Figure 2. Benefit of the creation of new database references for the detection of rare pathogens. (a) MALDI-TOF mass spectrum of a clinical strain recovered from an
ear swab; (b) Despite the good quality of the spectrum with many distinct peaks, the identification software yields no good matches with the standard database; (c)
Identification results of other clinical strains some months later after the creation of custom database references (MSPs).
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Although the spectrum showed a lot of clearly defined peaks
the software could not find any matching reference spectra
(Figure 2(b); log(score) value = 1.365; for identification at high
confidence level a log(score) ≥ 2.000 is expected).
Conventional methods were not successful either.
Definitive identification could be achieved by 16S rRNA
sequencing and resulted in Auritidibacter ignavus, a gram-
positive rod-shaped bacterium that had been described
about one year earlier [106]. The type strain of this species
had been isolated from an ear swab of a man with otitis
externa. From the bacterial biomass, a new custom MSP
was created for the local MALDI-TOF MS system. With this
new MSP, two other isolates could be identified from
routine samples within the following month. These were
also confirmed as A. ignavus by sequencing and were used
for MSP creation. This enabled the detection of this until-
then unseen species (Figure 2(c)). In the following years
until March 2019, these new reference spectra were hit in
isolates from routine more than 200 additional times,
mostly from cultures from ear swabs. This example shows
the strength of MALDI-TOF MS for finding new (rare) bac-
teria again from clinical samples (unpublished data). This
also contributes to the growing knowledge in medical
microbiology as the clinical significance of microorganisms
can now be easily assessed.
This approach, with the creation of new MSPs whenever
good spectra from routine isolates are found with no match in
the reference libraries, can also be used to find yet unnamed
microorganisms. Sometimes the sequences can already be
found in public databases, but there have not been any valid
publications for these new species. In the laboratory in
Dortmund, for isolates that cannot be identified even after
sequencing, MSPs with generic names will be created. Using
this method it is possible to track the reoccurrence of these
unnamed species in clinical routine. With more than 25 of
these MSPs included in the database for research purposes
the regular reoccurrence of these species in clinical samples
can be seen (Table 3).
Again, this example underlines the power of MALDI-TOF
MS for the detection and description of new and rare
bacteria together with the opportunity to gain information
about clinical significance in daily routine.
6. Rapid adaption of MALDI-TOF MS identification
to emerging pathogens
The ability of current MALDI-TOF MS systems to easily extend
databases also enables the possibility to rapidly include emerging
pathogens. This is possible because users are able to create own
references with high quality for their in-house database if the
manufacturer of a system gives clear guidance for the procedure
and quality control, as the quality of a database has to be strictly
controlled from sample preparation to quality control [107]. In
2016 the Centers for Disease Control (CDC) investigated outbreaks
with Elizabethkingia anophelis causing serious infections with fatal-
ities in the midwest of the United States (Nicholson 2016). Usually,
Elizabethkingia species can be found in the environment and
rarely cause infections. The CDC could quickly react and supple-
ment their own MALDI Biotyper database. Subsequently, the
commercial databases could be extended for easy identification
of this new pathogen. The CDC hosted resource MicrobeNet [108]
can play a key role in the rapid reaction on emerging infectious
agents. As the CDC is collecting difficult to identify organisms in
the USA nationwide, it has the capability to create references for
its MALDI-TOF MS database very soon after a pathogen’s appear-
ance. Thereby, these references can be made available to MALDI
Biotyper users via the MicrobeNet embedded library before com-
mercial suppliers expand their own databases.
Similarly, new reference entries in (commercial) MALDI-TOF
MS databases can help to recognize emerging pathogens. An
example for this is Klebsiella pneumoniae which initially was
divided into three phylogroups, KpI-III, and then phylogenetic
analyses led to the differentiation as distinct species
K. pneumoniae, K. quasipneumoniae and K. variicola [109].
Differentiation with conventional methods was difficult and
special molecular analysis was needed. MALDI-TOF MS can
easily distinguish these new species that formerly all have
been identified just as K. pneumoniae if the database is prop-
erly established, as shown for the MALDI Biotyper system,
recently [110]. Now there are reports stating, that K. variicola
might be more virulent as it is a frequent cause of blood-
stream infections [111].
7. Expert opinion
Before MALDI-TOF mass spectrometry was introduced into
clinical microbiology laboratories, diagnostics in bacteriology
were expected to move towards culture-free molecular tech-
nologies. The long turnaround times, limited detectable
microbe spectrum, and frequently low precision of culture-
dependent techniques seemed to justify the acceptance of
the drawbacks of methods based on molecular biology, i.e.
high costs and mainly targeted approaches.
With MALDI-TOF MS and broad reference databases as
a powerful diagnostic tool, this picture changed dramatically.
It did not only improve the present diagnostic but also
enables knowledge generation for future diagnostics. The
observation of such microbes during infections expands the
knowledge about their relation to diseases as well as resis-
tance trends. This will enable a better diagnosis and treatment
of such infections in the future, e.g. adopted antibiotic sus-
ceptibility tests can be developed. The diagnostic gap which
Table 3. The 10 most frequently hit MSPs of presumably not yet described
bacterial species in the laboratory in Dortmund (MVZ Dr. Eberhard & Partner
Dortmund). According to the manufacturer log(score) values ≥ 2.000 are
regarded as identification at a high confidence level.
MSP [n] Average log(score)
NONAME Corynebacterium sp. 312 2.137
NONAME Haemophilus sp. 185 2.248
NONAME Pseudomonas sp. 158 2.366
NONAME Pantoea sp. 156 2.366
NONAME Pseudoclavibacter-like bacterium 101 2.140
NONAME Peptoniphilus sp. (1) 97 2.144
NONAME Peptoniphilus sp. (2) 39 2.196
NONAME Enterobacter sp. 38 2.320
NONAME Acinetobacter sp. 24 2.022
NONAME Actinomycetaceae bacterium 23 2.033
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS 11
appears with emerging pathogens can be closed quickly by an
integration of specific references into diagnostic MALDI-TOF
MS systems, as shown for E. anophelis. As also yet unknown
pathogenic bacteria can be quickly integrated into databases,
their occurrence and relevance in infectious diseases can be
observed soon after their first detection.
In culturomics studies, this knowledge generation can be
performed on a large scale with affordable workload and
costs, not as a substitute but as a complement to metage-
nomic studies. The advantage of such an approach compared
to culture-free, molecular studies is the existence of viable
organisms which can be further analyzed after their detection.
This revival of culture-based diagnostics is also reflected by
the introduction of extensive laboratory automation of micro-
bial culture in an increasing number of laboratories today. It
can be speculated that this would not have happened without
the introduction of MALDI-TOF MS.
Now novel applications of MALDI-TOF MS are being devel-
oped, e.g. subspecies differentiation, typing, and antibiotic resis-
tance testing. It has yet to be seen which of these applications
will further expand the utility of the technology in microbiology
laboratories. Their success is not certain as such novel applica-
tions have to survive the competition of other upcoming tech-
nologies. The success of MALDI-TOF MS in the last 10 years, from
a technology unknown to nearly all clinical microbiologists, to
a workhorse technology accepted as standard worldwide, now
has lowered the hurdles of acceptance of novel technologies.
This catalyzed the introduction of new promising tools into
microbial diagnostics. Thereby, MALDI-TOF MS helped to
improve diagnostic practice not only by itself but also indirectly,
acting as a pioneering technology.
In the upcoming years, it can be expected that the trend to
use MALDI-TOF MS for identification and further microbiologi-
cal analyses will continue. Although the technology has been
in routine use now for about ten years, still the development
to improve speed and accuracy, as well as the addition of
novel applications, is ongoing. International studies using
shared databases and large-scale culturomics analyses will
broaden the knowledge about microbial diversity. Recently
disregarded pathogens will be detected and investigated
regarding their involvement in diseases. The MALDI-TOF MS
databases for microorganisms will further grow, and differen-
tiation of very closely related microorganisms by the novel,
improved bioinformatic algorithms will have the effect that
‘hard-to-identify’ will be a term only rarely attributed to bac-
teria in the future.
Automation within the laboratories will be a strong driver in
the development of this technology. An increasing number of
diagnostic microbiology laboratories are introducing partial or
total automation of microbial culture workflows. The lack of
well-trained and experienced technical staff will accelerate this
transformation. As a consequence, the sample preparation for
subsequent MALDI-TOF MS analysis is also being automated,
i.e. the automated transfer of colony material to the MALDI
target plate and the addition of matrix. Thus, the decision to
analyze a bacterial colony will be less dependent on the exper-
tise of a human specialist, but more in the direction of ‘in
doubt – better analyze’. Throughput ability and low costs of
MALDI measurements will allow such a change of routine.
The introduction of MALDI-TOF MS has already increased the
number of microbial identifications in routine diagnostics (obser-
vation in our own laboratories and from the feedback of Bruker
customers). This will further avoid the missing of rare, yet unrec-
ognized pathogens. In a final step, the automated transfer of
a prepared target into a mass spectrometer for subsequent mea-
surement and bioinformatic analysis will create microbial identifi-
cation workflows with minimal human intervention for the
majority of samples. MALDI-TOF MS will not only deliver precise
identification for an increasing number of pathogens but also
additional information about virulence and/or resistance.
MALDI-TOF MS-based resistance/susceptibility tests may
find their place in the laboratory, in particular for samples
that require a rapid phenotypical susceptibility information,
e.g. in the case of positive blood cultures [112].
In particular, slow-growing and biochemically inactive
organisms like anaerobes might benefit from such accelerated
phenotypic MALDI-TOF MS tests. Also, recently described
methods for direct detection of antibiotic resistance-causing
proteins [113] or analysis of bacterial lipid modifications [114]
might find their way into routine diagnostics. Such develop-
ments will partially require different MALDI matrices and dif-
ferent measurement modes. More analyses directly from
clinical samples are intended, but here the limited sensitivity
of MALDI-TOF MS and its low performance in the analysis of
mixtures will be limiting factors.
Such developments are partially in competition with rapid
molecular tests or other fast phenotypic approaches. The advan-
tage of mass spectrometry will be that there are already several
thousand instruments for such analyses available in diagnostic
laboratories, and the increasing speed of measurement of mod-
ern systems enables the transfer of additional tests.
It is difficult to estimate to what extent MALDI-TOF MS will
take over additional parts of microbial diagnostics, but for sure
it will keep and probably strengthen its position as the labora-
tory standard for broad routine identification of pathogens.
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